Ênio Bassi

Prof. Ênio Bassi

Universidade Federal de Alagoas
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
VAVinicius Andrade-Oliveira
Vinicius Andrade-Oliveira
MAMariane T. Amano
Mariane T. Amano
MCMatheus Correa-Costa
Matheus Correa-Costa
ACAngela Castoli
Angela Castoli
RFRaphael Jose Ferreira Felizardo
Raphael Jose Ferreira Felizardo
NCNiels Olsen Saraiva Camara
Niels Olsen Saraiva Camara
Short-chain fatty acids (SCFAs) are fermentation end products produced by the intestinal microbiota and have anti-inflammatory and histone deacetylase–inhibiting properties. Recently, a dual relationship between the intestine and kidneys has been unraveled. Therefore, we evaluated the role of SCFA in an AKI model in which the inflammatory process has a detrimental role. We observed that therapy with the three main SCFAs (acetate, propionate, and butyrate) improved renal dysfunction caused by injury. This protection was associated with low levels of local and systemic inflammation, oxidative cellular stress, cell infiltration/activation, and apoptosis. However, it was also associated with an increase in autophagy. Moreover, SCFAs inhibited histone deacetylase activity and modulated the expression levels of enzymes involved in chromatin modification. In vitro analyses showed that SCFAs modulated the inflammatory process, decreasing the maturation of dendritic cells and inhibiting the capacity of these cells to induce CD4+ and CD8+ T cell proliferation. Furthermore, SCFAs ameliorated the effects of hypoxia in kidney epithelial cells by improving mitochondrial biogenesis. Notably, mice treated with acetate-producing bacteria also had better outcomes after AKI. Thus, we demonstrate that SCFAs improve organ function and viability after an injury through modulation of the inflammatory process, most likely via epigenetic modification.

13 September 2012 in Diabetes
Verified
Journal Article
Open access
PDF file
ÊBÊnio Bassi
Ênio Bassi
Pedro M Moraes-VieiraPedro M Moraes-Vieira
Pedro M Moraes-Vieira
CMCarla S.R. Moreira-Sá
Carla S.R. Moreira-Sá
DADanilo Candido Almeida
Danilo Candido Almeida
LVLeonardo M. Vieira
Leonardo M. Vieira
NCNiels Olsen Saraiva Camara
Niels Olsen Saraiva Camara
Adipose-derived mesenchymal stem cells (ADMSCs) display immunosuppressive properties, suggesting a promising therapeutic application in several autoimmune diseases, but their role in type 1 diabetes (T1D) remains largely unexplored. The aim of this study was to investigate the immune regulatory properties of allogeneic ADMSC therapy in T cell–mediated autoimmune diabetes in NOD mice. ADMSC treatment reversed the hyperglycemia of early-onset diabetes in 78% of diabetic NOD mice, and this effect was associated with higher serum insulin, amylin, and glucagon-like peptide 1 levels compared with untreated controls. This improved outcome was associated with downregulation of the CD4+ Th1-biased immune response and expansion of regulatory T cells (Tregs) in the pancreatic lymph nodes. Within the pancreas, inflammatory cell infiltration and interferon-γ levels were reduced, while insulin, pancreatic duodenal homeobox-1, and active transforming growth factor-β1 expression were increased. In vitro, ADMSCs induced the expansion/proliferation of Tregs in a cell contact–dependent manner mediated by programmed death ligand 1. In summary, ADMSC therapy efficiently ameliorates autoimmune diabetes pathogenesis in diabetic NOD mice by attenuating the Th1 immune response concomitant with the expansion/proliferation of Tregs, thereby contributing to the maintenance of functional β-cells. Thus, this study may provide a new perspective for the development of ADMSC-based cellular therapies for T1D.

24 May 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ACAngela Castoli
Angela Castoli
TBTárcio Teodoro Braga
Tárcio Teodoro Braga
MCMatheus Correa-Costa
Matheus Correa-Costa
Cristhiane Favero AguiarCristhiane Favero Aguiar
Cristhiane Favero Aguiar
ÊBÊnio Bassi
Ênio Bassi
NCNiels Olsen Saraiva Camara
Niels Olsen Saraiva Camara
The aim of this study was to investigate the role of TLR2, TLR4 and MyD88 in sepsis-induced AKI. C57BL/6 TLR2−/−, TLR4−/− and MyD88−/− male mice were subjected to sepsis by cecal ligation and puncture (CLP). Twenty four hours later, kidney tissue and blood samples were collected for analysis. The TLR2−/−, TLR4−/− and MyD88−/− mice that were subjected to CLP had preserved renal morphology, and fewer areas of hypoxia and apoptosis compared with the wild-type C57BL/6 mice (WT). MyD88−/− mice were completely protected compared with the WT mice. We also observed reduced expression of proinflammatory cytokines in the kidneys of the knockout mice compared with those of the WT mice and subsequent inhibition of increased vascular permeability in the kidneys of the knockout mice. The WT mice had increased GR1+low cells migration compared with the knockout mice and decreased in GR1+high cells migration into the peritoneal cavity. The TLR2−/−, TLR4−/−, and MyD88−/− mice had lower neutrophil infiltration in the kidneys. Depletion of neutrophils in the WT mice led to protection of renal function and less inflammation in the kidneys of these mice. Innate immunity participates in polymicrobial sepsis-induced AKI, mainly through the MyD88 pathway, by leading to an increased migration of neutrophils to the kidney, increased production of proinflammatory cytokines, vascular permeability, hypoxia and apoptosis of tubular cells.

1 September 2011 in Stem Cell Reviews and Reports
Verified
Journal Article
Closed access
PDF file
ÊBÊnio Bassi
Ênio Bassi
DADanilo Candido Almeida
Danilo Candido Almeida
Pedro M Moraes-VieiraPedro M Moraes-Vieira
Pedro M Moraes-Vieira
NCNiels Olsen Saraiva Camara
Niels Olsen Saraiva Camara

22 November 2013 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
Pedro M Moraes-VieiraPedro M Moraes-Vieira
Pedro M Moraes-Vieira
RLRafael A. Larocca
Rafael A. Larocca
ÊBÊnio Bassi
Ênio Bassi
JPJean Pierre S. Peron
Jean Pierre S. Peron
VAVinicius Andrade-Oliveira
Vinicius Andrade-Oliveira
NCNiels Olsen Saraiva Camara
Niels Olsen Saraiva Camara
Leptin is an adipose‐secreted hormone that plays an important role in both metabolism and immunity. Leptin has been shown to induce Th1‐cell polarization and inhibit Th2‐cell responses. Additionally, leptin induces Th17‐cell responses, inhibits regulatory T (Treg) cells and modulates autoimmune diseases. Here, we investigated whether leptin mediates its activity on T cells by influencing dendritic cells (DCs) to promote Th17 and Treg‐cell immune responses in mice. We observed that leptin deficiency (i) reduced the expression of DC maturation markers, (ii) decreased DC production of IL‐12, TNF‐α, and IL‐6, (iii) increased DC production of TGF‐β, and (iv) limited the capacity of DCs to induce syngeneic CD4+ T‐cell proliferation. As a consequence of this unique phenotype, DCs generated under leptin‐free conditions induced Treg or TH17 cells more efficiently than DCs generated in the presence of leptin. These data indicate important roles for leptin in DC homeostasis and the initiation and maintenance of inflammatory and regulatory immune responses by DCs.

10 October 2018 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
PDF file
ITIthallo S. B. Tanabe
Ithallo S. B. Tanabe
ETEloiza L. L. Tanabe
Eloiza L. L. Tanabe
ESElane C. Santos
Elane C. Santos
WMWanessa V. Martins
Wanessa V. Martins
IAIsadora M. T. C. Araújo
Isadora M. T. C. Araújo
ÊBÊnio Bassi
Ênio Bassi
Chikungunya virus (CHIKV) is a re-emergent arthropod-borne virus (arbovirus) that causes a disease characterized primarily by fever, rash and severe persistent polyarthralgia. In the last decade, CHIKV has become a serious public health problem causing several outbreaks around the world. Despite the fact that CHIKV has been around since 1952, our knowledge about immunopathology, innate and adaptive immune response involved in this infectious disease is incomplete. In this review, we provide an updated summary of the current knowledge about immune response to CHIKV and about soluble immunological markers associated with the morbidity, prognosis and chronicity of this arbovirus disease. In addition, we discuss the progress in the research of new vaccines for preventing CHIKV infection and the use of monoclonal antibodies as a promising therapeutic strategy.